



Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

Medical benefit drug policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and therefore subject to change.

**Effective Date: 06/08/2023**

**Pulmonary Arterial Hypertension Products**

- Flolan<sup>®</sup> (epoprostenol)
- Remodulin<sup>®</sup> (treprostinil)
- Tyvaso<sup>®</sup> (treprostinil)
- Uptravi<sup>®</sup> (selexipag)
- Veletri<sup>®</sup> (epoprostenol)

**HCPCS:** Flolan/Veletri - J1325; Remodulin - J3285; Tyvaso - J7686; Uptravi – J3490;

**Policy:**

*Requests must be supported by submission of chart notes and patient specific documentation.*

- A. Coverage of the requested drug is provided when all the following are met:
  - a. FDA approved indication
  - b. FDA approved age
  - c. If the requested drug is listed below, the member must meet the additional criteria listed:

Drug(s)	Criteria
Tyvaso	<ul style="list-style-type: none"> <li>• For pulmonary hypertension associated with interstitial lung disease (PH-ILD; World Health Organization (WHO) Group 3) - no further criteria are required.</li> <li>• Pulmonary Arterial Hypertension (PAH) WHO Group 1 - trial and failure, intolerance or contraindication to all of the following               <ul style="list-style-type: none"> <li>○ Generic sildenafil or tadalafil</li> <li>○ Generic ambrisentan or bosentan</li> </ul> </li> </ul>

This policy and any information contained herein is the property of Blue Cross Blue Shield of Michigan and its subsidiaries, is strictly confidential, and its use is intended for the P&T committee, its members and BCBSM employees for the purpose of coverage determinations.

Drug(s)	Criteria
Uptravi injection	<ul style="list-style-type: none"> <li>• Trial and failure, intolerance or contraindication to all of the following: <ul style="list-style-type: none"> <li>○ Generic sildenafil or tadalafil</li> <li>○ Generic ambrisentan or bosentan</li> <li>○ Adempas</li> </ul> </li> <li>• Currently stable on oral Uptravi therapy</li> <li>• Will be used as short-term bridging therapy in those patients temporarily unable to take oral therapy</li> </ul>

- d. Trial and failure, contraindication, or intolerance to the preferred drugs as listed in BCBSM/BCN's prior authorization and step therapy documents and/or BCBSM/BCN's utilization management medical drug list

\*\*\*Note: This policy pertains to Medicare Part B only\*\*\*

**B. Quantity Limitations, Authorization Period and Renewal Criteria**

- a. Quantity Limits: Align with FDA recommended dosing
- b. Authorization Period: One year at a time unless specified below
  - i. Uptravi injection: 60 days
- c. Renewal Criteria: Clinical documentation must be provided to confirm that current criteria are met and that the medication is providing clinical benefit unless specified below.
  - i. Uptravi injection: Not applicable as no further authorization will be provided

\*\*\*Note: Coverage may differ for Medicare Part B members based on any applicable criteria outlined in Local Coverage Determinations (LCD) or National Coverage Determinations (NCD) as determined by Center for Medicare and Medicaid Services (CMS). See the CMS website at <http://www.cms.hhs.gov/>. Determination of coverage of Part B drugs is based on medically accepted indications which have supported citations included or approved for inclusion determined by CMS approved compendia.

**Background Information**

- FDA approved indications for medications covered in this policy:
  - Epoprostenol: A prostacyclin vasodilator indicated for the treatment of PAH (WHO Group I) to improve exercise capacity. Studies establishing effectiveness included predominantly patients with New York Heart Association (NYHA) Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases.
  - Treprostinil: A prostacyclin vasodilator indicated for:
    - Treatment of PAH (WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).
    - Patients who require transition from epoprostenol, to reduce the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition.
  - Uptravi: A prostacyclin receptor agonist indicated for the treatment of PAH (WHO Group 1) to delay disease progression and reduce the risk of hospitalization for PAH.

This policy and any information contained herein is the property of Blue Cross Blue Shield of Michigan and its subsidiaries, is strictly confidential, and its use is intended for the P&T committee, its members and BCBSM employees for the purpose of coverage determinations.

- CHEST 2019 guideline-supported therapies for WHO Functional Class II and III include: sildenafil, tadalafil, ambrisentan, bosentan, macitentan, riociguat, treprostinil inhalation, and iloprost inhalation.
- Additional CHEST 2019 guideline-supported therapies for WHO Functional Class III and IV include: epoprostinil IV and treprostinil IV/SQ, and in those who cannot use IV/SQ, treprostinil inhalation and iloprost inhalation.
- PDE5Is and ERAs are clinically effective guideline-supported therapies that have wide utility per CHEST guideline recommendations and are cost effective as they are available as generics.
- Opsumit (macitentan) has no clinical advantages over ambrisentan and bosentan at this time, as all three ERAs are now FDA approved to prevent disease progression and clinical worsening. Ambrisentan and bosentan are more cost effective therapies as they are available generically.
- CHEST 2019 guidelines suggest initial monotherapy with ERA, PDE5I, or Adempas (riociguat) for treatment of WHO Functional Class II or III, and suggest adding a second class if inadequate response to initial monotherapy.
- CHEST 2019 guidelines suggest adding a third drug class in WHO Class III or IV with deterioration.
- CHEST 2019 guidelines suggest inhaled prostacyclins (Tyvaso (treprostinil), Ventavis (iloprost)) for WHO Class III after failure of one or two classes of oral agents.
- Cross benefit opportunities may exist to step on drugs on the medical benefit for prostacyclin drugs per guidelines, as SQ/IV therapy is preferred to inhalation for WHO Class III and WHO Class IV. Prostacyclin SQ/IV medications may be more cost-effective, however require more complex administration. Further investigation is warranted.
- Upravi (selexipag) and Orenitram ER (treprostinil tablets) were found to have insufficient clinical evidence to support a guideline recommendation per the CHEST 2019 guidelines. Utilization of guideline supported agents is promoted by step therapy.
- Per package labeling, in Upravi (selexipag) clinical trials at baseline, 80% of patients were being treated with a stable dose of an ERAs (15%), a PDE5Is (32%), or both (33%).
- Per FDA label, Adempas (riociguat) should not be used in combination with a PDE5I.
- Pulmonary hypertension (PH) with interstitial lung disease and pulmonary fibrosis can be treated with IV or inhaled treprostinil. PDE5Is have shown little or no benefit in these patients. ERAs, specifically ambrisentan, have been shown to be ineffective and associated with adverse effects in patients with PH while bosentan and macitentan are ineffective in idiopathic pulmonary fibrosis (IPF) but have not been tested in IPF associated PH.
- Upravi's prospective, multicenter, open-label, single-sequence, cross-over, Phase III study showed the safety, tolerability and pharmacokinetics of temporarily switching between oral Upravi and Upravi IV in 20 patients. Patients who were stable on oral Upravi switched to IV Upravi for three infusions including the morning and evening dose on Day 1, and morning dose of Day 2 before switching back to the oral formulation in the evening of Day 2.

## References:

1. Micromedex. DrugDex. Accessed 9/14/2020 [www.micromedex.com](http://www.micromedex.com).
2. Revatio Prescribing Information. New York, NY: Pfizer Labs. April 2020.
3. Adcirca Prescribing Information. Indianapolis, IN: Eli Lilly. August 2020

This policy and any information contained herein is the property of Blue Cross Blue Shield of Michigan and its subsidiaries, is strictly confidential, and its use is intended for the P&T committee, its members and BCBSM employees for the purpose of coverage determinations.

4. Tracleer Prescribing Information. South San Francisco, CA: Actelion Pharmaceuticals. July 2021.
5. Letairis Prescribing Information. Foster City, CA: Gilead Sciences. August 2019.
6. Opsumit Prescribing Information. South San Francisco, CA: Actelion Pharmaceuticals. October 2021.
7. Upravi Prescribing Information. South San Francisco, CA: Actelion Pharmaceuticals October 2021.
8. Adempas Prescribing Information. Whippany, NJ: Bayer HealthCare. September 2021 .
9. Orenitram ER Prescribing Information. Research Triangle Park, NC; United Therapeutics Corp. May 2021.
10. Tyvaso Prescribing Information. Research Triangle Park, NC; United Therapeutics Corp. March 2021.
11. Tyvaso DPI Prescribing Information. Research Triangle Park, NC; United Therapeutics Corp. May 2022.
12. Ventavis Prescribing Information. Titusville, NJ: Actelion Pharmaceuticals. March 2022.
13. Tadiq (tadalafil) [Prescribing Information]. Farmville, NC; CMP Pharma, Inc. June 2022.
14. Liqrev [prescribing information]. Farmville, NC; CMP Pharma, Inc. April 2023.
15. Klinger, et al. PAH WHO Group 1 CHEST Guidelines 2019. CHEST, 2019. [https://journal.chestnet.org/article/S0012-3692\(19\)30002-9/abstract](https://journal.chestnet.org/article/S0012-3692(19)30002-9/abstract)
16. FDA Drug Safety Communication: FDA recommends against use of Revatio in children with pulmonary hypertension. August 30, 2012. [cited September 11, 2012]; Available from: <http://www.fda.gov/Drugs/DrugSafety/ucm317123.htm>
17. The Regence Group. Preliminary Medication Review: Cardiovascular: sildenafil suspension. September 2012.
18. The Regence Group. Medical Policy for Adcirca and Cialis. July 2012.
19. McLaughlin VV, Badesch DB, Farber HW, et al for the American College of Cardiology Foundation Task Force. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association. *Circulation* 2009; 119:2250-94.
20. Michelakis E et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension. *Circulation* 2002; 105:2398.
21. Ghofrani HA et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. *Lancet* 2002; 360:895-900.
22. Ghofrani HA et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. *Am J Respir Crit Care Med* 2003; 167:1139.
23. Jackson G et al. Sildenafil for primary pulmonary hypertension: short and long-term symptomatic benefit. *Int J Clin Pract* 2002; 56(5):397-8.
24. Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. *Circulation*. 2009 Jun 9; 119(22):2894-903. Epub 2009 May 26. PubMed PMID: 19470885.
25. Marion, DW. Pulmonary hypertension. In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2013.
26. Therapeutic Class Review<sup>SM</sup>. Pulmonary Arterial Hypertension (PAH): Updated for treprostinil (Tyvaso™), tadalafil (Adcirca™), sildenafil (Revatio®), treprostinil (Remodulin®) iloprost (Ventavis®). The Regence Group. July 2010.
27. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. *Chest* 2007; 131:1917.
28. BCBSA Technology Evaluation Center. TEC Specialty Pharmacy Report #15-2013 and #16-2013: Macitentan (Opsumit) and Riociguat (Adempas). October 2013.
29. Galie N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, et al. Updated treatment algorithm of pulmonary arterial hypertension. *J Am Coll Cardiol* 2013;62:D60-72.
30. McLaughlin VV, Gaine, SP, Howard LS, Leuchte HH, Mathier MA, Mehta S, et al. Treatment goals of pulmonary hypertension. *J Am Coll Cardio* 2013;62:D73-81.
31. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, et al. Definitions and diagnosis of pulmonary hypertension. *J Am Coll Cardio* 2013;62:D42-50.
32. United Therapeutics Corp. FDA approved Orientram™ (treprostinil) extended-release tablets for the treatment of pulmonary arterial hypertension. Silver Springs, MD: United Therapeutics, 23 December 2013. Web 14 February 2014.

This policy and any information contained herein is the property of Blue Cross Blue Shield of Michigan and its subsidiaries, is strictly confidential, and its use is intended for the P&T committee, its members and BCBSM employees for the purpose of coverage determinations.

Policy History												
#	Date	Change Description										
2.1	Effective Date: 06/08/2023	Addition of Liqrev										
2.0	Effective Date: 08/04/2022	Updated to add Tyvaso DPI formulation and Tadiq										
1.9	Effective Date: 10/10/2021	Annual review of medical policy. Criteria applies to Medicare Part B only.										
1.8	Effective Date: 06/10/2021	Updated policy with specific step therapy for certain medications following CHEST 2019 guidelines and included Tyvaso's new indication for PH-ILD; WHO Group 3										
1.7	Effective Date: 06/11/2020	Annual Review of Medical Policy										
1.6	Effective Date: 06/06/2019	Added trial and failure of preferred products statement										
1.5	Effective Date: 02/14/2019	Annual Review of Medical Policy										
1.4	Effective Date: 07/05/2017	UM medical management system update for MAPPO and BCNA for Flolan, Remodulin, Tyvaso, Veletri, and Ventavis <table border="1" data-bbox="496 848 1373 1058" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th>Line of Business</th> <th>PA Required in Medical Management System (Yes/No)</th> </tr> </thead> <tbody> <tr> <td>BCBS</td> <td>No</td> </tr> <tr> <td>BCN</td> <td>No</td> </tr> <tr> <td>MAPPO</td> <td>Yes</td> </tr> <tr> <td>BCNA</td> <td>Yes</td> </tr> </tbody> </table>	Line of Business	PA Required in Medical Management System (Yes/No)	BCBS	No	BCN	No	MAPPO	Yes	BCNA	Yes
Line of Business	PA Required in Medical Management System (Yes/No)											
BCBS	No											
BCN	No											
MAPPO	Yes											
BCNA	Yes											
1.3	Effective Date: 08/14/2014	Add QL to Orenitram and updated information on dosing, safety, pregnancy & lactation, adverse effects										
1.2	Effective Date: 05/08/2014	Criteria Update: Updated to include Orenitram										
1.1	Effective Date: 02/06/2014	Criteria Update										
1.0	Effective Date: 02/07/2013	Criteria Update										

\* The prescribing information for a drug is subject to change. To ensure you are reading the most current information it is advised that you reference the most updated prescribing information by visiting the drug or manufacturer website or <http://dailymed.nlm.nih.gov/dailymed/index.cfm>.